NumerixS Investment Technologies Inc acquired a new stake in Charles River Laboratories Intl. Inc (NYSE:CRL) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 1,600 shares of the medical research company’s stock, valued at approximately $227,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. BlackRock Inc. grew its stake in Charles River Laboratories Intl. by 1.6% during the 2nd quarter. BlackRock Inc. now owns 4,660,628 shares of the medical research company’s stock valued at $661,344,000 after acquiring an additional 72,827 shares in the last quarter. AQR Capital Management LLC lifted its holdings in shares of Charles River Laboratories Intl. by 18.0% in the 1st quarter. AQR Capital Management LLC now owns 2,082,761 shares of the medical research company’s stock worth $301,042,000 after acquiring an additional 317,001 shares during the last quarter. Bank of New York Mellon Corp increased its stake in Charles River Laboratories Intl. by 49.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 978,183 shares of the medical research company’s stock worth $138,804,000 after buying an additional 323,625 shares during the period. TimesSquare Capital Management LLC increased its stake in Charles River Laboratories Intl. by 5.1% during the 2nd quarter. TimesSquare Capital Management LLC now owns 907,850 shares of the medical research company’s stock worth $128,824,000 after buying an additional 44,275 shares during the period. Finally, Fisher Asset Management LLC increased its stake in Charles River Laboratories Intl. by 6.8% during the 2nd quarter. Fisher Asset Management LLC now owns 471,341 shares of the medical research company’s stock worth $66,883,000 after buying an additional 29,980 shares during the period. 94.31% of the stock is owned by institutional investors.

A number of research firms recently commented on CRL. Leerink Swann began coverage on shares of Charles River Laboratories Intl. in a research report on Monday, June 10th. They issued an “outperform” rating on the stock. ValuEngine lowered shares of Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. Zacks Investment Research upgraded shares of Charles River Laboratories Intl. from a “hold” rating to a “buy” rating and set a $150.00 target price on the stock in a research report on Wednesday. Svb Leerink started coverage on shares of Charles River Laboratories Intl. in a research report on Monday, June 10th. They set an “outperform” rating and a $155.00 target price on the stock. Finally, SunTrust Banks upped their target price on shares of Charles River Laboratories Intl. from $156.00 to $162.00 and gave the stock a “buy” rating in a research report on Monday. Six research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $149.54.

NYSE CRL traded up $2.39 during trading hours on Thursday, reaching $138.21. 138,374 shares of the company traded hands, compared to its average volume of 281,115. Charles River Laboratories Intl. Inc has a 12 month low of $103.00 and a 12 month high of $149.07. The company has a current ratio of 1.59, a quick ratio of 1.38 and a debt-to-equity ratio of 1.47. The stock has a market capitalization of $6.55 billion, a PE ratio of 22.92, a PEG ratio of 1.72 and a beta of 1.09. The company has a 50 day moving average of $131.21 and a two-hundred day moving average of $135.98.

Charles River Laboratories Intl. (NYSE:CRL) last posted its quarterly earnings results on Wednesday, July 31st. The medical research company reported $1.63 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.55 by $0.08. The company had revenue of $657.60 million for the quarter, compared to the consensus estimate of $662.61 million. Charles River Laboratories Intl. had a net margin of 8.94% and a return on equity of 22.01%. The company’s revenue for the quarter was up 12.4% on a year-over-year basis. During the same period last year, the firm posted $1.62 EPS. On average, equities research analysts anticipate that Charles River Laboratories Intl. Inc will post 6.52 earnings per share for the current year.

In other news, insider David Ross Smith sold 1,249 shares of Charles River Laboratories Intl. stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $130.36, for a total value of $162,819.64. Following the transaction, the insider now owns 19,327 shares of the company’s stock, valued at approximately $2,519,467.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 1.80% of the stock is currently owned by company insiders.

Charles River Laboratories Intl. Profile

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Further Reading: How Do Mutual Funds Work?

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories Intl. Inc (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.